- Economic Evaluation of Factorial Studies
- Evidence Synthesis
- Mapping between quality of life measures
- Dealing with Uncertainty in Economic Evaluation
- Breeman S, Campbell M K, Dakin H, Fiddian N, Fitzpatrick R, Grant A, Gray A, Johnston L, Maclennan G S, Morris R W, and Murray D W (2013) Five-year results of a randomised controlled trial comparing mobile and fixed bearings in total knee replacement. Bone Joint J, 95-B(4):486-92.
- Dakin H and Wordsworth S (2013) Cost-minimisation analysis versus cost-effectiveness analysis, revisited. Health Econ, 22(1):22-34.
- Dakin Helen, Gray Alastair, and Murray David (2013) Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score. Qual Life Res, 22(3):683-94.
- Dakin H, Gray A, Fitzpatrick R, Maclennan G, Murray D, and Trial Group &KAT (2012) Rationing of total knee replacement: a cost-effectiveness analysis on a large trial data set. BMJ Open, 2(1):e000332.
- IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, and Reeves BC (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology, 119(7):1399-411.
|Tel||+44 (0)1865 289 422|
|Fax||+44 (0)1865 289 271|
|College||St Cross College|
Helen Dakin joined the Health Economics Research Centre in February 2008. Before starting at HERC, she worked at Abacus International and completed her MSc in Economic Evaluation in Healthcare at City University. She previously graduated from Cambridge University with Masters and Batchelor's degrees in Biochemistry.
Her current projects include the KAT trial, which assesses the cost-effectiveness of different types of knee replacement component, and the IVAN trial, which assesses the cost-effectiveness of bevacizumab (Avastin) and ranibizumab (Lucentis) in age-related macular degeneration.
Helen is also undertaking a DPhil at the University of Oxford on the optimal methods for conducting economic evaluations of factorial clinical trials.